RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliffWhat's next ? - The pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, particularly now that soon-to-come generic competition is on the horizon with Big Pharmas looming patent cliff, according to PwC.
To mitigate this emerging threat Big Pharma will seek to ramp-up innivation and it's M&A activities. Of interest for Big Pharma hunting for biotechs are early-stage companies and "bolt-on" transactions, that are in the range of US$5 Billion to US$15 Billion.
As an early-mid stage biotech company with the complementary drug pelareorep to immune checkpoint inhibitors, ONCY is well-positioned as a "bolt-on" acquisition for Big Pharma, with immune checkpoint inhibitors, PARP inhibitors, CAR-T and bi-specific therapies, like as those companies discussed on this message board.
Furthermore, ONCY's biomarkers will enable oncologists/doctors to identify which patients would most benefit from the IO combination of pelareorep + immune checkpoint inhibitors, as well as further giving these doctors the ability to monitor the benefit of the IO combination throughout the course of therapy.